FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Spotfire, a business unit of Cloud Software Group, provides powerful, self-service analytics for data-intensive businesses. Today, Spotfire announced The Analytics Forum (TAF), to be hosted virtually September 19-21. This long-running annual event provides attendees the opportunity to hear inspiring keynotes, learn from real-world success stories, and gain key insights on how to solve some of the biggest data challenges that companies face. Today’s leader

Spotfire Set to Host The Analytics Forum: Analytics for Insight and Action

Paid advertisement by bioMérieux. The COVID-19 pandemic demonstrated there is tremendous clinical value associated with having fast, accurate, and easy-to-use diagnostics as close to the patient as possible. The newly developed, FDA-cleared, and CLIA-waived BIOFIRE® SPOTFIRE® system by bioMérieux, brings the power of PCR testing directly to point-of-care facilities, such as urgent care clinics among many others. This changes everything. For the first time, outpatient clinics can provide patients with results in 15 minutes for a suspected common respiratory infection, enabling clinicians to administer optimized and data-driven antibiotic therapy. The core technology behind SPOTFIRE® is based on methods developed by Dr. Carl Wittwer and Dr. Jared Farrar at the University of Utah and patented in 2021. Wittwer and Farrar discovered how to speed up PCR testing and make the diagnostic tool more accessible outside of the hospital laboratory. This kind of innovation represents one of the core pillars of bioMérieux’s growth strategy, rooted in longstanding entrepreneurial tradition. In 2014, bioMérieux acquired Utah-based BioFire Diagnostics, Inc. Since then, the company has heavily invested in its local operations, including a new headquarters facility and a major manufacturing center. Differentiating between a viral or bacterial cause for a respiratory infection is valuable because the results can help healthcare providers decide how best to treat a patient and reduce unnecessary antibiotic use in their practices at the same time. The improper use of antibiotics fuels the global health threat of antimicrobial resistance (AMR). AMR occurs when bacteria, fungi, viruses, and parasites mutate over time and no longer respond to existing medicines. The most recent evidence shows that roughly 1.27 million deaths were directly attributable to AMR and nearly 5 million deaths were associated in some way with AMR in 2019. Without effective antibiotics, every infection has the potential to become life-threatening. According to the CDC, 80 to 90% of all human antibiotic use happens in outpatient settings and 30 to 50% of those antibiotic prescriptions are unnecessary or inappropriate. “We are proud to deliver such an innovative syndromic testing technology at the point of care. We believe the BIOFIRE® SPOTFIRE® solution is a real game changer in patient care, allowing physicians to give patients an accurate and rapid diagnosis, using only one test during the actual patient visit,” said Pierre Boulud, Chief Executive Officer of bioMérieux. As a family-owned company since 1963, bioMérieux has grown to become a world leader in the field of in vitro diagnostics and is proud to be a part of the innovative business community found across Utah. With its North American headquarters facility in Salt Lake City, the bioscience firm has nearly 3,500 local employees driven daily by an unrelenting commitment to improve public health worldwide. Eighty percent of bioMérieux’s R&D budget is dedicated toward bringing game-changing solutions to the market, like SPOTFIRE®, to assist healthcare professionals identify infections quickly, ensuring optimal patient care, and fighting against the threat of AMR. 1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis [published correction appears in Lancet. 2022 Oct 1;400(10358):1102]. Lancet. 2022;399(10325):629-655. doi:10.1016/S0140-6736(21)02724-0
2. Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of inappropriate antibiotic prescriptions among U.S. ambulatory care visits, 2010–2011. JAMA 2016;315:1864–73. http://dx.doi.org/10.1001/jama.2016.4151external icon
Share:

Sponsored: Pioneered in Utah – The value of innovative diagnostics

Today at 02:42 am
bioMérieux - First-Half 2023 Results
€1,770 million in first-half 2023 sales, up 8.3% like-for-like; organic growth excluding respiratory panels amounts to +11%, slightly ahead of the full-year sales growth guidance excluding respiratory panels of +8 to +10%. Q2 sales organic growth at 9.2% driven by a strong momentum in clinical microbiology (+18%) and BIOFIRE® non-respiratory panels (+23%) combined with a solid growth in industrial applications (+10%)
Contributive operating income before non-recurring items reached €291 million (16.5% of sales) for the first half of the year, decreasing by 1.5% like for like versus H1 2022, as expected. Promising start of the new BIOFIRE® SPOTFIRE®, VIDAS® KUBE™ and VITEK® REVEAL™ instruments and a very positive trend for VITEK® MS PRIME. Pierre Boulud, Chief Executive Officer, said: "bioMérieux performed well in the first half of 2023, in line with its targets, illustrating the relevance of our product portfolio to support the fight against infectious diseases and antimicrobial resistance. In addition, we have successfully launched several new products,that will reinforce our leadership in the market. We do confirm our annual guidance." Marcy l'Étoile (France), September 1st, 2023 - The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on August 31st under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2023. Consolidated data
H1 2023
1.93 €
SALES
NB: Unless otherwise stated, sales growth is expressed at constant exchange rates and scope of consolidation (like-for-like). Consolidated sales amounted to €1,770 million in first-half 2023, a robust growth like-for-like of 8.3% from €1,658 million in the prior-year period including a 2% price increase contribution. Reported growth stood at 6.8% impacted by a €25 million negative currency effect, primarily due to the devaluation of Latin America and Asian currencies, as well as the Turkish lira, partly compensated by the appreciation of the US dollar against the euro. Evolution of sales
1,658
0
138
1,770
+6.8%
NB: A definition of the currency effect and of changes in the scope of consolidation is provided at the end of this press release. ANALYSIS OF SALES BY APPLICATION
Q2
Including R&D-related revenue arising on industrial applications. Six
1,770.1 1,658.0 +6.8% +8.3%
Clinical applications sales (84% of the consolidated total), rose by more than 9% year-on-year to €724 million in the second quarter of 2023, up 8% in first-half to €1,484 million. Inmolecular biology, sales growth was driven by a 23% increase in the demand for BIOFIRE® non- respiratory panels, while the sales of respiratory panels decreased slightly by 4.5%, in the context of a decline of the COVID-19 pandemic. The BIOFIRE® installed base expanded by 300 instruments, reaching more than 24,300 units at June 30, 2023. Themicrobiology business delivered a remarkable 18% growth led by strong reagents sales in all key ranges thanks to both volumes and prices increases, as well as high level of equipment sales supported mainly by VITEK® MS Prime and Lab Efficiency WASP® ranges. Inimmunoassays, sales growth resumed in the second quarter, led by routine and emergency assays, partly offset by the procalcitonin downward trend, as expected. Industrial applications sales, (around 16% of the consolidated total), increased by nearly 10% year- on-year to €141 million in the second quarter. Growth has been fueled by reagents, especially microbiology and molecular ranges, and by equipments. Around half of the 9.3% growth reported for the first six months of the year comes from price increases. ANALYSIS OF SALES BY REGION
Q2 Q2
(1) Including Europe, the Middle East and Africa. Sales in theAmericas (50% of the consolidated total) reached €429 million in second quarter 2023, a growth of nearly 6% versus the same period in 2022, whereas first-half sales increased by 6% to stand at €884 million. InNorth America (43% of the consolidated total), the quarterly performance has been led by the strong demand in BIOFIRE® non-respiratory panels and hemoculture reagents, partially compensated by the lower demand for BIOFIRE® respiratory panel. Equipment sales have grown double-digit, driven by VITEK® MS Prime and Lab Efficiency WASP® solutions. Latin America (7% of the consolidated total) recorded an excellent performance in the second quarter with double-digit sales growth for all the key reagent ranges. Sales in theEurope - Middle East - Africa region (33% of the consolidated total) came to €283 million for the second quarter with a solid growth like-for-like of more than 8%. In Europe, robust sales growth has been reported in all microbiology key ranges, together with a very strong growth in non-respiratory BIOFIRE® panels sales. Sales in theAsia-Pacific region (18% of the consolidated total) came to €153 million in the second quarter of 2023, up nearly 22% compared with the same period in 2022. China is recovering strongly, on a favorable basis of comparison with the lockdown situation last year, and India delivered a solid growth thanks to sustained sales in microbiology and molecular biology. CONSOLIDATED INCOME STATEMENT
Contributive operating income
For the six months to June 30, 2023, contributive operating income decreased by 9.5% year-on-year to €291 million, representing 16.5% of sales. The reported figure includes an unfavorable currency effect of €13.5 million, and a negative perimeter effect of €11.2 million. At constant exchange rate and scope of consolidation, contributive operating income decreased by 1.5% compared with first-half 2022. Gross profit stood at €999 million, or 56.4% of sales, nearly unchanged in percentage from 56.6% in the half-year 2022. At constant rate and perimeter of consolidation, the gross profit rate improved by 0.5pp, mainly thanks to the favorable evolution of transport costs. Selling, general and administrative expenses amounted to €502 million, or 28.4% of sales, compared with 26.6% in first-half 2022. On a like-for-like basis, they rose by 14,9%, mainly due to the return to the pre-pandemic levels of sales and marketing expenses as well as employee costs increase, including the impact of the broad success of MyShare, the worldwide employee share ownership plan. Amounting to a total expense for the company of €10 million, the MyShare plan allowed more than 5,600 employees to purchase 300,000 bioMérieux shares. R&D expenses amounted to €227 million, or 12.8% of sales, compared with €207 million and 12.5% one year earlier. These expenses increased by 5% on a like-for-like basis mainly due to the increase in employee costs. Other operating income amounted to around €21 million, down from €32 million in first-half 2022 mainly explained by capital gain on a building disposal in the US last year. Operating income
The amortization and impairment of acquisition-related intangible assets and acquisition costs amounted to €84 million, up from the €25 million in first-half 2022, as a consequence of the impairment recognized on the Hybiome acquisition goodwill for this 67% owned Chinese company specialized in immunoassays. As a result, the Group ended the first-half 2022 with an operating income of €208 million, down 30% on the €297 million reported during the same period one year earlier. Net income
Net financial result amounted to +€0.5 million over the period versus -€5.6 million recorded in 2022 thanks to financial interest on cash and lower hedging costs. The cost of net debt came to +€1.9 million in first-half 2023 versus -€2.9 million in first-half 2022, and other financial income and expenses totaled -€1.4 million, compared to -€2.7 million in first-half 2022. The Group's effective tax rate stood at 33.4 % on June 30, 2023, versus 22.4% in first-half 2022 mainly due to the impact of the Hybiome acquisition goodwill impairment. Net income, Group share amounted to €162 million in 2023, down €228 million in first-half 2022. CASH MANAGEMENT AND FINANCE
Free cash flow
EBITDA1 came to €394 million in first-half 2023, or 22.3% of sales, down 5% from the €414 million reported for the same period one year earlier. The decrease reflects the reduction in operating income compared to the first-half 2022. Income tax paid represented €110 million, a decrease from the €145 million paid in the first six months of 2022, primarily due to 2021 exceptional results. Working capital requirement rose by €153 million in first-half 2023. The change was primarily a result of the following items:
▪
▪
inventories rose by €115 million during the period, in preparation for winter season and due to the inventory build-up for the launch of new products. trade receivables diminished by €64 million mainly thanks to the collection of the US 2022 year-end sales and trade payables came down €15 million in line with the seasonality of the activity. 1 EBITDA corresponds to the aggregate of operating income before non-recurring items, and operating depreciation and amortization. other working capital requirement items increased by €87 million, primarily due to annual bonus payment. Capital expenditures represented around 8% of sales or €150 million in first-half 2023, versus €137 million in first-half 2022. Main capital expenditures were related to manufacturing and automation investments in Salt Lake City and Saint-Louis sites as well as the new manufacturing plant in Suzhou, China. In light of the above, free cash flow came in at €1 million in first-half 2023, compared to €16 million in first-half 2022. Change in net debt
Dividend of €100 million has been paid in first-half 2023, to be compared with €101 million in 2022. As a result, consolidated net debt came to €68 million as of June 30, 2023, versus a net cash of €47 million as of December 31, 2022. This net debt includes the discounted liability related to leases amounting to €103 million (IFRS16). 2023 OBJECTIVES
In light of itsfirst-half2023 performance, bioMérieux confirms the 2023 full year guidance released in March for both sales and contributive operating income beforenon-recurringitems. ▪
▪
As a reminder, excluding respiratory panels, sales growth for 2023 is expected to reach +8% to +10% at constant exchange rates and scope of consolidation, driven by a solid growth of BIOFIRE® non- respiratory panels as well as Microbiology and Industrial applications. Assuming a slowdown for respiratory panels sales, total Group sales would be evolving within a +4% to +6% range on a like-for-like basis. Contributive operating income beforenon-recurringitems should be in a range of €600 million to €630 million, at forecasted exchange rates, including a €40 million estimated unfavorable foreign exchange impact. SIGNIFICANT EVENTS OF THE FIRST HALF
bioMérieux evolves its governance: Alexandre Mérieux becomes Executive Chairman. Pierre Boulud is appointed Chief Executive Officer and Jennifer Zinn is appointed Executive Vice President of Clinical Operations. As of June 14th, 2023, bioMérieux announced that on a proposal of Alexandre Mérieux, Chairman and CEO, the Board of Directors of bioMérieux approved on June 13th, 2023 (effective July 1st, 2023), the appointments of Alexandre Mérieux as Executive Chairman and of Pierre Boulud as Chief Executive Officer. Pierre Boulud has been a member of the Executive Committee for seven years, including the last three years as Chief Operating Officer. As of June 27th, the Company announced the appointment of Jennifer Zinn as Executive Vice President of Clinical Operations, effective August 1st, 2023.
bioMérieux receives US FDA 510(k) clearance and CLIA-waiver for the for the fast and innovative BIOFIRE® SPOTFIRE® System and its BIOFIRE® SPOTFIRE® Respiratory (R) Panel and BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini
In H1, bioMérieux announced having received the U.S. Food and Drug Administration (FDA) 510(k) clearance and the U.S. Food and Drug Administration (FDA) Clinical Laboratory Improvement Amendments (CLIA) waiver for its fast and innovative BIOFIRE® SPOTFIRE® System and the BIOFIRE® SPOTFIRE® Respiratory (R) Panel and BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini. The new BIOFIRE® SPOTFIRE® R Panel Mini detects five of the most common viral causes of upper respiratory tract infections: SARS-CoV-2 (virus associated with COVID-19), Influenza A, Influenza B, Respiratory Syncytial Virus (RSV), and Rhinovirus, in about 15 minutes. Attachments

BioMerieux : First-Half 2023 Results

Save for later
NEW YORK – BioMérieux announced on Tuesday that its BioFire SpotFire Respiratory Panel Mini has obtained CLIA wavier from the US Food and Drug Administration. The SpotFire R Panel Mini detects SARS-CoV-2, influenza A and B, respiratory syncytial virus, and rhinovirus, the five most common viral causes of upper respiratory infections. The sample-to-answer SpotFire test system is the first FDA-cleared PCR system to provide results in under 20 minutes, BioMérieux said in a statement. It can run both a large multiplex respiratory tests of approximately 12 to25 pathogens and a small multiplex respiratory test for three to five pathogens. The system and associated panels are intended to expand BioMérieux's presence in the US outpatient market, the firm said. BioMérieux obtained clearance and CLIA waiver from FDA for the system and a 15-target assay called the BioFire SpotFire Respiratory Panel in February, and obtained 510(k) clearance for the mini panel in April. The rhinovirus target in the mini panel is intended to increase the diagnostic yield of the assay. "The inclusion of rhinovirus into this syndromic panel increases clinicians' ability to provide their patients with a definitive result compared to the other respiratory tests" that are available in the US and only contain the other viruses, Mark Miller, executive VP and chief medical officer at BioMérieux, said in a statement..
CLIA waiver now allows the system and its two existing respiratory panels to be used by non-lab professionals at the point of care. "CLIA waiver for BioFire SpotFire facilitates use in any clinical setting where patients seek care; be it an urgent care, physician office, local pharmacy, student health clinic, or emergency department," Jennifer Zinn, general manager and head of clinical operations for North America at BioMérieux, said in a statement. With a 15-minute time to result, the system "has the potential to improve clinical decisions, optimize clinical operations, and most importantly, support antimicrobial stewardship at the individual provider level," Zinn also said.

BioMérieux Gets CLIA Waiver for BioFire SpotFire Respiratory Panel Mini

04/17
04/27/2023 | 01:17am EDT
Message :
Solid first-quarter sales performance with an organic growth of +7.5%
This robust performance has been fueled by BIOFIRE® non-respiratory panels growing a remarkable +32%, while respiratory panels remained positive at +3%
Very good performance also in microbiology (+12%) and industrial applications (+9%)
As a result, total non-respiratory sales organic growth reached +8.8%, in line with full-year guidance
Strong momentum of product launches: key milestones have been achieved especially on
VITEK® REVEAL™, BIOFIRE® SPOTFIRE® and VIDAS® KUBE™ fronts
bioMérieux confirms its 2023 outlook for sales and operating profit, as published on March 8th
Alexandre Mérieux, Chairman and Chief Executive Officer, said: "bioMérieux had a good dynamic in this first-quarter,the company delivered a solid sales performance both in clinical and industrial applications. In line with its commitment to innovation for enhanced diagnostic, bioMérieux also had a strong momentum in terms of collaboration and key product launches." Marcy l'Étoile (France), April 27th, 2023 - bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31th, 2023. SALES
Consolidated- sales totaled €906 million in the first quarter of 2023, up 8.2% from €837 million in the year earlier period. Organic growth (at constant exchange rates and scope of consolidation) stood at +7.5%, in line with expectations. Exchange rate movements resulted in a positive currency effect of €6 million, mainly reflecting a stronger euro versus the US dollar. Analysis of sales
Including R&D-related revenue arising on industrial applications. Clinical applications sales, which account for approximately 84% of the consolidated total, increased by 7.2% year-on-year to €760 million in the first quarter of 2023. In molecular biology, the sales performance for BIOFIRE® non-respiratory reagents has been remarkable, overall up 32%, with a consistent growth across the portfolio and the regions. Respiratory panels sales grew 3% despite a decrease of demand since February, linked to the early slow-down of the respiratory pathogens season. BIOFIRE® installed base increased by 500 new systems, bringing the total to around 24,000 units. In microbiology, sales performance has been very robust for reagents, led by VITEK® automated ID/AST and BACT/ALERT® blood culture ranges, and including price increases in these ranges. Sales growth for equipment has been strong in key ranges. In immunoassays, the routine assays have pursued their return to positive growth, started in Q3 2022, while procalcitonin assays continued to experience downward trends in the US and in China. Industrial applications sales, which represent around 16% of the consolidated total, increased by a robust +9% year-on-year to €145 million, fueled by a high single-digit growth in reagents sales, and notably a remarkable business trend in healthcare segment.  ANALYSIS OF SALES BY REGION
Q1
Including Europe, the Middle East and Africa. Note: Unless otherwise stated, growth is expressed year-on-year at constant exchange rates and scope of consolidation (like-for-like). p. 2 | 5
Sales in the Americas (half of the consolidated total) reached €455 million in the first quarter, up 6.5% compared to the same period last year. In North America (44% of the consolidated total), sales performance has been fueled by the growth of BIOFIRE® non-respiratory panels and, to a lesser extent, respiratory panels as well as BACT/ALERT® blood culture assays, slightly offset by the decrease in immunoassay PCT. In Latin America, quarterly organic sales performance has been robust, reflecting a solid momentum in microbiology reagents sales. Sales in the Europe - Middle East - Africa region (32% of the consolidated total) came to €288 million in the first three months, up 8% year-on-year. This strong performance has been driven by BIOFIRE® non- respiratory panels sales, as well as microbiology key ranges. Sales in the Asia Pacific region (18% of the consolidated total) amounted to €163 million in the first quarter, up nearly 9% organically compared with €154 million in the same period of 2022. Growth has been led by reagents sales in India and equipment sales in China. FIRST-QUARTER OPERATING HIGHLIGHTS AND SUBSEQUENT EVENTS
US FDA 510(k) clearance for the BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini
In April 2023, bioMérieux has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the fast and accurate multiplex PCR*-based BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini. bioMérieux will immediately apply for Clinical Laboratory Improvement Amendments (CLIA) waiver for the test. The new BIOFIRE® SPOTFIRE® R Panel Mini detects five of the most common viral causes of upper respiratory tract infections: SARS-CoV-2 (virus associated with COVID-19), Influenza A, Influenza B, Respiratory Syncytial Virus (RSV), and Rhinovirus, in about 15 minutes. Oxford Nanopore and bioMérieux to enter into a strategic partnership agreement
In April 2023, Oxford Nanopore Technologies plc, the company delivering a new generation of nanopore- based molecular sensing technology, and bioMérieux SA announced that they have teamed up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics market. Initial areas of collaboration will include a test for determining antibiotic resistance of tuberculosis; an assay to identify pathogens in normally sterile clinical samples; and validating Oxford Nanopore's sequencing platform with BIOMÉRIEUX EPISEQ® CS application for rapid infection outbreak monitoring in patient-care settings. bioMérieux submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the VITEK® REVEAL™, formerly known as SPECIFIC REVEAL™ Rapid AST System
This rapid, modular, antimicrobial-susceptibility test platform that can deliver actionable results for Gram- negative bacteria directly from positive blood cultures in an average of five and a half hours enabling same-day treatment decision-making for patients suffering from bacteremic sepsis. The rapid AST system VITEK® REVEAL™ is already available on-market under CE-IVDD (assay panel) and IVDR (instrument) designation across Europe. The FDA 510(k) clearance will allow its commercialization in the U.S. and other countries recognizing this authorization. BioFire Defense partners with BARDA to accelerate development of the SPECIFIC REVEALTM Rapid AST System
In March 2023, bioMérieux announced that BioFire Defense, LLC, its affiliate and leader in pathogen detection systems for the U.S Department of Defense, has received a contract from the Biomedical Advanced Research and Development Authority, to accelerate development of the Specific Diagnostics SPECIFIC REVEALTM Rapid AST System, a rapid, modular, antimicrobial-susceptibility test platform that can deliver phenotypic results in an average of five and a half hours from positive blood cultures. Note: Unless otherwise stated, growth is expressed year-on-year at constant exchange rates and scope of consolidation (like-for-like). p. 3 | 5
bioMérieux launches BIOFIRE® FIREWORKSTM a cutting-edge,data-driven software solution that takes BIOFIRE Systems to the next level
In April 2023, bioMérieux announced the launch of this innovative solution, optimizing laboratory services and supporting data-driven decisions. This software is the newest addition to the BIOMERIEUX VISION SUITE, the company's portfolio of Data and IT Solutions supporting increased efficiency and productivity in laboratories worldwide. New MyShare 2023 worldwide employee share ownership plan
As of May 3, 2023, bioMérieux eligible team members will be able to purchase shares of bioMérieux stock (directly or indirectly in the case of French employees) at a discount and with a matching employer contribution. The new plan will once again offer eligible team members an opportunity to take part in the Company's success. The plan was approved by the Board of Directors on December 14, 2022 and is open to any team member in countries where such plans are authorized by local legislation. The subscription period will run from May 3 to May 22, with settlement and delivery in the following weeks, in accordance with applicable laws and regulations. INVESTOR CALL
bioMérieux will hold an investor presentation on Thursday, April 27th, 2023 at 2:00 pm Paris time (GMT+1). The presentation will be conducted in English and will be accessible via webcast. Notes and definitions
The above forward-looking statements are based, entirely or partially, on assessments or judgments that may change or be modified, due to uncertainties and risks related to the Company's economic, financial, regulatory and competitive environment, notably those described in the 2022 Universal Registration Document. Accordingly, the Company cannot give any assurance nor make any representation as to whether the objectives will be met. The Company does not undertake to update or otherwise revise any forecasts or objectives presented herein, except in compliance with the disclosure obligations applicable to companies whose shares are listed on a stock exchange. Currency effect: this is established by converting actual numbers at the average rates of year y-1. In practice, those rates are either average rates communicated by the ECB, or hedged rates if hedging instruments have been set up. Argentina and Turkey are considered in bioMérieux's accounts since 2022 in a state of hyperinflation. Impacts of hyperinflation in accordance with IAS 29 in the Company's accounts are excluded in the calculation of Like-for-Like growth. Changes in scope of consolidation: these are determined:
for acquisitions in the period, by deducting from sales for the period the amount of sales generated during the period by acquired entities as from the date they entered the consolidated reporting scope;
for acquisitions in the previous period, by deducting from sales for the period the amount of sales generated in the months in the previous period during which the acquired entities were not consolidated;
for disposals in the period, by adding to sales for the period the amount of sales generated by entities sold during the previous period in the months of the current period during which these entities were no longer consolidated;
for disposals in the previous period, by adding to sales for the period the amount of sales generated during the previous period by the entities Sold
Note: Unless otherwise stated, growth is expressed year-on-year at constant exchange rates and scope of consolidation (like-for-like). p. 4 | 5
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics for 60 years, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2022, revenues reached €3.6 billion, with over 90% of sales outside of France. bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the Euronext Paris stock market. Symbol: BIM - ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP
CONTACTS

BioMerieux : BioMérieux &ndash; First-Quarter 2023 Business Review

Teradata (NYSE: TDC) is a cloud analytics and data platform. Teradata helps businesses make better decisions by providing them with insights into their data. It serves industries such as manufacturing, retail, healthcare, and more. It was founded in 1979 and is based in San Diego, California.

Teradata

`` Tight integration between Spotfire 5 and Teradata Corporation greatly improves our customers ' decision-making ability in a way that previously challenged business users , '' said Rob Berman , vice president for global alliances at Teradata Corporation .

Spotfire Harnesses Teradata for Executing Complex Calculations and Predictive Analytics In-database.
TIBCO Spotfire Announces Expanded Partnership with Teradata to Offer Extreme Data Discovery and Analytics.

General Electric (NYSE: GE) manufactures industrial machinery equipment. The company manufactures aerospace engines, gas and steam turbines, onshore and offshore wind turbines, and more. It operates in a variety of industries, including aviation, healthcare, power, renewable energy, and transportation. It was founded in 1889 and is based in Boston, Massachusetts.

General Electric

In-Q-Tel identifies and partners with companies developing technologies to help deliver these solutions to the Central Intelligence Agency and the broader U.S. Intelligence Community (IC) to further their missions. Launched by the CIA as a private, independent, not-for-profit organization, IQT was created to bridge the gap between the technology needs of the Intelligence Community and new advances in commercial technology. Similar to a corporate strategic fund, IQT operates for strategic investments rather than financial investments benefits to its customers in the Intelligence Community.

In-Q-Tel

TIBCO Software

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Acquired

Unattributed VC

Unattributed VC - II

Series C

Series D

Spotfire offers an analytical applications platform targeting the Fortune 2000 companies.

Spotfire

RapidMiner is a data analytics and machine learning software provider. It is a predictive analytics platform, that provides solutions for a variety of industries. The platform is used by business analysts. RapidMiner was formerly known as Rapid-I. The company was founded in 2007 and is based in Boston, Massachusetts. In September 2022, RapidMiner was acquired by Altair. The terms of the transaction were not disclosed.

Tableau Software is a provider of visual analysis and reporting solutions. Its flagship product is used by managers, business intelligence professionals, business analysts, strategic consultants, financial professionals, market researchers, scientists and engineers in nearly every industry. The company was founded in 2003 and is based in Seattle, Washington.

Dan Kogan

Director

By                         Jenni Spinner
Acquired in 2018, the data analytics provider formerly known as Shyft Analytics will now be part of the company’s Acorn by AI unit. Two years after its purchase by Medidata, the Shyft Analytics unit will operate as the Commercial Data Solutions (CDS) team at Acorn AI. Outsourcing-Pharma (OSP) recently spoke with Bruno Lempernesse (BL)—senior vice president of Commercial Data Solutions and real-world evidence for Acorn AI by Medidata, a Dassault Systèmes company—about CDS what the division’s capabilities might mean for clinical trial professionals. OSP: Please tell us about Shyft Analytics.​
BL: Shyft Analytics, a cloud-based data analytics provider for life sciences companies, was founded in 2004. Its Data Analytics Platform, designed for the pharmaceutical and biotech industries, transforms massive amounts of complex health data into high quality clinical and commercial insights. The Shyft platform integrates healthcare data from commercial distribution networks, data vendors, and multiple third-party systems into its cloud platform. It then translates the data into customized insights and analytics to clinical and commercial clients. In 2016, Medidata and Shyft first formed a commercial partnership to increase access to healthcare data in clinical trials by providing insights to life sciences companies to help identify specific patient populations for studies across therapeutic areas, supporting customer efforts to design more effective protocols, improving study participant recruitment, and uncovering the best treatment paths in clinical practice for patients. Shyft was acquired by Medidata in 2018, and since that time Shyft has contributed to Medidata’s vision of bridging the gap from clinical to real-world data (RWD) and commercialization. We are applying these capabilities to expand Medidata’s existing suite of products beyond clinical trials into commercial launch, data management and insight generation. It was recently announced that Shyft is now part of Acorn AI, by Medidata, which is changing the commercialization paradigm, connecting R&D activities and commercialization in new ways. The platform provides industry leading capabilities to combine clinical and real-world insights, enabling customers to accelerate their therapies as scientific breakthroughs continue to create more precise drugs that target specific patient characteristics. OSP: What does this shift (no pun intended) to the Acorn AI by Medidata brand signify to customers and potential clients?​
BL: We established the CDS team to focus on connecting R&D, commercialization technologies, and services. As part of Acorn AI, by Medidata, CDS includes all of the solutions and support developed by Shyft Analytics. Our new organization signifies Medidata’s commitment to delivering leading applications, services, technology solutions, and proven data science capabilities. The combined platform and brand unification is powered by the largest global pool of research and real-world data (RWD) sources; it gives customers and potential clients the ability to better analyze clinical, real-world and commercial data to achieve their goals—all under one company umbrella. OSP: Could you please provide a little more detail about what CDS will be offering its clients—specifically, what services and capabilities make it stand out from the competition?​
Bruno Lempernesse, senior VP of Commercial Data Solutions and real-world evidence, Acorn AI by Medidata
BL: The CDS team at Acorn AI, by Medidata has the technology and expertise to support life science companies throughout the entire commercial drug lifecycle. CDS has more than 15 years of experience in commercial data management, and through the investment we make in STRATA and LUMEN, our end-to-end data management platform and insights solution, and QUANTUM, our Real-World Evidence (RWE) platform, CDS ensures customers are operating with the latest life sciences data management and insights technology; this includes Commercial Data Warehousing, Master Data Management, Report Development, Commercial Launch Roadmap, Data Procurement, and RWD analysis. CDS also provides solutions to optimize field sales call planning and outreach by moving beyond traditional healthcare provider (HCP) segmentation and applying advanced analytics for greater accuracy. CDS uses prescription, distribution, and claims data to improve targeting, Market Access and reimbursement, treatment adherence, and targeted HCP messaging. All this is built on CDS’s robust, flexible, and scalable commercial data model, which ingests data from over 300 different sources, integrating, aggregating, and normalizing any kind of life sciences data into a flexible, scalable data warehouse that can drive performance and insights across the enterprise. This data model supports a “bring your own tool” framework, enabling users to create customer reports through a client-preferred business intelligence tool. With faster, more accurate insights, CDS allows customers to find more patients, remove barriers to treatment, and maximize adherence. Acorn AI’s CDS team combines the high-quality data sources with Medidata’s proprietary suite of tools and processes to make better sense of RWD. Using diagnosis codes, treatment analogues and demographic information through QUANTUM, data scientists and researchers can find pockets of untreated or undiagnosed patients by conducting a complex line of therapy analyses. Acorn AI’s network of partnerships facilitates data acquisition as an independent party, which matches customers’ key questions to the most relevant data. Copyright - Unless otherwise stated all contents of this web site are © 2020 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions

Medidata shifts its Commercial Data Solutions unit

Download
Acorn AI: Solutions for All Phases of the Commercial Drug Lifecycle (Graphic: Business Wire)
August 19, 2020 01:35 PM Eastern Daylight Time
NEW YORK--( BUSINESS WIRE )--Medidata, a Dassault Systèmes company, global leader in creating end-to-end solutions to support the entire clinical trial process, announced that SHYFT Analytics will officially be adopting the Acorn AI, by Medidata brand. The innovative commercial and data analytics technologies and services valued by SHYFT customers will be operating as the Commercial Data Solutions (CDS) team at Acorn AI. SHYFT Analytics was acquired by Medidata in 2018. Acorn AI, built on data, AI technologies and domain expertise developed over the last 20 years by Medidata, helps life sciences companies answer the questions that matter. Current solutions include:
Intelligent Trials to improve study success by providing real-time operational insights
Synthetic Control Arms for diseases where a randomized control is not feasible
Trial Design that brings together insights from historic clinical trials and contemporaneous real-world use to improve overall probability of success
Commercial Data Solutions that help therapies accelerate launch and peak patient adoption
“We are excited to bring our combined capabilities to customers under a unified Acorn AI brand,” said Sastry Chilukuri, president, Acorn AI by Medidata. “Scientific breakthroughs continue to create more precise drugs that target specific patient characteristics. This is changing the commercialization paradigm, connecting R&D and Commercial in new ways. Our live platform provides industry leading capabilities to combine Clinical and Real-world insights and help customers accelerate their therapies to patients.”
Acorn AI’s Commercial Data Solutions team is led by Bruno Lempernesse, who was previously CEO of Inflexxion, a technology software SaaS solutions company with clinical assessment tools, Real World Clinical Data and predictive analytics used by healthcare organizations, providers, pharmaceutical companies and regulatory authorities in the space of substance use disorders, like opioid addiction. Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization. About Medidata
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,500 customers and partners access the world's most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata , The Operating System for Life SciencesTM. About Acorn AI
Acorn AI, by Medidata, a Dassault Systèmes company, combines data, technology, and deep expertise to help life sciences companies deliver actionable insights across the entire continuum of clinical development. Acorn AI’s advanced analytics answers the most important questions in R&D and commercialization including accelerating breakthrough innovation, optimizing study execution and commercial success, and demonstrating the value of therapies. Built upon the Medidata platform comprising 20,000+ trials and more than six million patients, Acorn AI products feature the industry’s largest structured, standardized clinical trial data repository connected with real world, translational, and other datasets. For more information, please visit www.medidata.com/acornai . About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual experience twins of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production. Dassault Systèmes brings value to more than 270,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com . 3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, EXALEAD, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries. Contacts

Acorn AI, by Medidata Launches Commercial Data Solutions, Broadening its Analytics Offering Across Clinical, Real World and Commercialization

NEW YORK–(BUSINESS WIRE)–Medidata, a Dassault Systèmes company, global leader in creating end-to-end solutions to support the entire clinical trial process, announced that SHYFT Analytics will officially be adopting the Acorn AI, by Medidata brand. The innovative commercial and data analytics technologies and services valued by SHYFT customers will be operating as the Commercial Data Solutions (CDS) team at Acorn AI. SHYFT Analytics was acquired by Medidata in 2018. Acorn AI, built on data, AI technologies and domain expertise developed over the last 20 years by Medidata, helps life sciences companies answer the questions that matter. Current solutions include:
Intelligent Trials to improve study success by providing real-time operational insights
Synthetic Control Arms for diseases where a randomized control is not feasible
Trial Design that brings together insights from historic clinical trials and contemporaneous real-world use to improve overall probability of success
Commercial Data Solutions that help therapies accelerate launch and peak patient adoption
“We are excited to bring our combined capabilities to customers under a unified Acorn AI brand,” said Sastry Chilukuri, president, Acorn AI by Medidata. “Scientific breakthroughs continue to create more precise drugs that target specific patient characteristics. This is changing the commercialization paradigm, connecting R&D and Commercial in new ways. Our live platform provides industry leading capabilities to combine Clinical and Real-world insights and help customers accelerate their therapies to patients.”
Acorn AI’s Commercial Data Solutions team is led by Bruno Lempernesse, who was previously CEO of Inflexxion, a technology software SaaS solutions company with clinical assessment tools, Real World Clinical Data and predictive analytics used by healthcare organizations, providers, pharmaceutical companies and regulatory authorities in the space of substance use disorders, like opioid addiction. Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization. About Medidata
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,500 customers and partners access the world’s most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata , The Operating System for Life SciencesTM. About Acorn AI
Acorn AI, by Medidata, a Dassault Systèmes company, combines data, technology, and deep expertise to help life sciences companies deliver actionable insights across the entire continuum of clinical development. Acorn AI’s advanced analytics answers the most important questions in R&D and commercialization including accelerating breakthrough innovation, optimizing study execution and commercial success, and demonstrating the value of therapies. Built upon the Medidata platform comprising 20,000+ trials and more than six million patients, Acorn AI products feature the industry’s largest structured, standardized clinical trial data repository connected with real world, translational, and other datasets. For more information, please visit www.medidata.com/acornai . About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual experience twins of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production. Dassault Systèmes brings value to more than 270,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com . 3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, EXALEAD, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries. Contacts

Zack King, Founder and CEO of SHYFT Analytics; SVP of Medidata
Zack helms the SHYFT ship, where he’s responsible for communicating his vision for the company and navigating it toward success. His goal is to help SHYFT become the largest cloud company in life science analytics. BEYOND WORK: In the winter, Zack retreats to the mountains where he’s enjoyed shredding the slopes on his snowboard for the past 30 years. During the summer, you’ll find him battling the ocean waves as he races his sailboat. Where did the idea for SHYFT Analytics originate? It started when one of the largest pharmaceutical companies hired my team to build a next-generation analytics platform for its flagship oncology drug. We spent more than two years architecting and building the earliest versions of the software. We charted new territory, connecting hundreds of data sources to understand how the drug was being used in the real world and what factors drove prescribing behavior. When did you realize that the technology you were building could become the start of a company? The original customer launch was successful, and it was then that we knew we had hit on something. It turned out that most pharmaceutical companies were struggling with similar challenges. I founded SHYFT based on the original platform we built and grew the business organically for several years. I had an incredible founding team who are all still with us today. We charted new territory, connecting hundreds of data sources to understand how the drug was being used in the real world and what factors drove prescribing behavior.”  
 
How did those early experiences in biotech and consulting shape the product you offer today? Our foundation as biotech industry experts was crucial early on. We knew the pharmaceutical industry inside and out from our experience as consultants, and most of us came from a software engineering background. That gave us a unique and differentiated relationship with early customers, who we partnered with for early product development and market fit. SHYFT Analytics was recently acquired by Medidata, another company bringing data to the healthcare industry. What opportunities does that acquisition provide for your team at SHYFT? Together, we’ve created the first company in life sciences that can close the loop on clinical and commercial insights. We’re able to power our customers’ digital transformations with real-world analytics and artificial intelligence to reduce risk, optimize revenue and help patients. Medidata’s global scale allows us to operate at a level we’ve never experienced before. We’re now backed by 2,500 employees, 1,200 pharmaceutical and biotech and medical device customers, who have offices in every major city and country and are equipped with enhanced capabilities in product, technology and data science. To keep up, we’re growing rapidly at SHYFT . We moved into a 117,000-square-foot headquarters in March, and we expect to hire between 600 and 800 new employees over the next five years. For our employees, this means there are even more opportunities to explore different career paths. What steps did you take to ensure a smooth transition for your team? We did a lot of upfront work to ensure that there would be a good fit between SHYFT and Medidata. I had gotten to know Medidata’s founders, Tarek and Glen, over the years, and more recently when they invested in our Series B. Working with original like-minded founders is special, and they’ve given us a ton of support to continue to grow the SHYFT business. We’ve also made sure to be very open and transparent with our team. We’ve always been ultra-transparent, but an acquisition can be frightening for people. We wanted to eliminate those fears by overcommunicating and answering questions and potential concerns well in advance. MORE ON SHYFT Meritocracy matters: How the culture at SHYFT analytics levels the playing field for all employees
 
How has your culture helped your team through this transition and set your team up for success? Our culture sets us apart from most companies, and I believe culture can be a competitive differentiator. We have a politics-free, collaborative culture where people can do amazing, smart and challenging work in a fun environment. We put our customers and each other at the center of everything we do. Our team is what makes SHYFT such a great place to work.

How SHYFT Analytics' founder charted a new course for the healthcare...

Parexel provides biopharmaceutical services that include a broad range of expertise-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology, and medical device industries. It offers clinical data management, decentralized clinical trials, medical writing, medical monitoring and consulting, and other services. The company was founded in 1982 and is based in Newton, Massachusetts.

Parexel

SHYFT Analytics , a Medidata Solutions company , and PAREXEL International Corporation , a leading innovator of global biopharmaceutical services , today announced that the companies have entered into a strategic partnership that establishes SHYFT Analytics 's technology as an integral part of PAREXEL International Corporation 's foundation for Real-World Evidence generation and outcomes research for biopharmaceutical and medical device clients .

PAREXEL and SHYFT Analytics Partner to Deliver Faster More Dynamic RealWorld Data Studies

Novartis (NYSE: NVS) researches, develops, manufactures, and markets healthcare products. It provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The company was founded in 1996 and is based in Basel, Switzerland.

Novartis

Tetraphase Pharmaceuticals operates as a biopharmaceutical company. It develops and commercializes novel tetracyclines for serious and life-threatening conditions, including bacterial infections caused by multidrug-resistant. Its products include fully synthetic Fluorocyclines and antibiotics for use as first-line empiric monotherapy. The company was founded in 2006 and is based in Watertown, Massachusetts. In July 2020, Tetraphase Pharmaceuticals was acquired by La Jolla Pharmaceuticals.

Tetraphase Pharmaceuticals

SHYFT Analytics

Medidata

J.Jill

Zefer Corporation

EF Education First

Series B

SHYFT Analytics, formerly Trinity Pharma Solutions, is a provider of cloud-based data, analytics and mobile solutions for the global life sciences industry. By connecting information across sources and channels, the company delivers multi-dimensional insights into customers and the behavior driving markets. Interactive and personalized insights are available in real-time on mobile devices powering better decisions from execs to sales teams.

Informatica (NYSE: INFA) provides artificial intelligence (AI) powered cloud data management solutions. It offers Informatica Intelligent Data Management Cloud (IDMC), a data management platform that connects, manages, and unifies data across any multi-cloud, hybrid system, democratizing data to modernize and advance its business strategies. It serves industries such as retail, manufacturing, healthcare, and more. The company was founded in 1993 and is based in Redwood City, California.

Valmont Industries (NYSE: VMI) provides engineered products and services for infrastructure development and agriculture facilities. Its major products include steel, aluminum, and composite pole, tower and other structures, concrete pole structures, and mechanized irrigation systems. The company also manufactures and distributes industrial and agricultural irrigation products in addition to a variety of fabricated products for commercial and industrial applications. Valmont Industries was founded in 1946 and is based in Omaha, Nebraska.

Wells Fargo Success Story

Professional Services

Platform Overview

Compare Spotfire vs SHYFT Analytics

Customers evaluate the quality of Spotfire's products using the following success metrics.